BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35296193)

  • 21. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention.
    Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A
    J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-hepatocellular carcinoma activity using human HepG2 cells and hepatotoxicity of 6-substituted methyl 3-aminothieno[3,2-b]pyridine-2-carboxylate derivatives: in vitro evaluation, cell cycle analysis and QSAR studies.
    Abreu RM; Ferreira IC; Calhelha RC; Lima RT; Vasconcelos MH; Adega F; Chaves R; Queiroz MJ
    Eur J Med Chem; 2011 Dec; 46(12):5800-6. PubMed ID: 22014996
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
    Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
    Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking.
    Eldehna WM; Fares M; Ibrahim HS; Aly MH; Zada S; Ali MM; Abou-Seri SM; Abdel-Aziz HA; Abou El Ella DA
    Eur J Med Chem; 2015 Jul; 100():89-97. PubMed ID: 26071861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of 1,6-Naphthyridin-2(1
    Zhang X; Wang Y; Ji J; Si D; Bao X; Yu Z; Zhu Y; Zhao L; Li W; Liu J
    J Med Chem; 2022 Jun; 65(11):7595-7618. PubMed ID: 35635004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
    Maher M; Kassab AE; Zaher AF; Mahmoud Z
    Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, and anticancer evaluation of arylurea derivatives as potent and selective type II irreversible covalent FGFR4 inhibitors.
    Wang M; Lan L; Wang YW; Zhang JY; Shi L; Sun LP
    Bioorg Med Chem; 2023 May; 87():117298. PubMed ID: 37196426
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
    El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA
    Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological evaluation of phenyl substituted polyoxygenated xanthone derivatives as anti-hepatoma agents.
    Dai M; Yuan X; Kang J; Zhu ZJ; Yue RC; Yuan H; Chen BY; Zhang WD; Liu RH; Sun QY
    Eur J Med Chem; 2013 Nov; 69():159-66. PubMed ID: 24013415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
    Gao L; Shay C; Lv F; Wang X; Teng Y
    Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, Synthesis,
    Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
    Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic Anticancer Strategy of Sonodynamic Therapy Combined with PI-103 Against Hepatocellular Carcinoma.
    Yang H; Jing H; Han X; Tan H; Cheng W
    Drug Des Devel Ther; 2021; 15():531-542. PubMed ID: 33603343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of pyrazolo[3,4-d]pyrimidines: Nitric oxide releasing compounds targeting hepatocellular carcinoma.
    Elshaier YAMM; Shaaban MA; Abd El Hamid MK; Abdelrahman MH; Abou-Salim MA; Elgazwi SM; Halaweish F
    Bioorg Med Chem; 2017 Jun; 25(12):2956-2970. PubMed ID: 28487127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis, anticancer assessment on human breast, liver and colon carcinoma cell lines and molecular modeling study using novel pyrazolo[4,3-c]pyridine derivatives.
    Metwally NH; Deeb EA
    Bioorg Chem; 2018 Apr; 77():203-214. PubMed ID: 29367077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design and synthesis of novel pyridopyrimidine derivatives with anchoring non-coplanar aromatic extensions of EGFR inhibitory activity.
    Eissa AAM; Aljamal KFM; Ibrahim HS; Abdelrasheed Allam H
    Bioorg Chem; 2021 Nov; 116():105318. PubMed ID: 34488123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
    Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
    Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor activity of BJ-1207, a 6-amino-2,4,5-trimethylpyridin-3-ol derivative, in human lung cancer.
    Gautam J; Banskota S; Chaudhary P; Dahal S; Kim DG; Kang HE; Lee IH; Nam TG; Jeong BS; Kim JA
    Chem Biol Interact; 2018 Oct; 294():1-8. PubMed ID: 30125546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma.
    Eissa IH; Ibrahim MK; Metwaly AM; Belal A; Mehany ABM; Abdelhady AA; Elhendawy MA; Radwan MM; ElSohly MA; Mahdy HA
    Bioorg Chem; 2021 Feb; 107():104532. PubMed ID: 33334586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, biological evaluation and molecular modeling of novel 2-amino-4-(1-phenylethoxy) pyridine derivatives as potential ROS1 inhibitors.
    Tian Y; Zhang T; Long L; Li Z; Wan S; Wang G; Yu Y; Hou J; Wu X; Zhang J
    Eur J Med Chem; 2018 Jan; 143():182-199. PubMed ID: 29174814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis, molecular docking and anti-hepatocellular carcinoma evaluation of novel acyclic pyridine thioglycosides.
    Elgemeie GH; Fathy NM; Farag AB; Alkhursani SA
    Nucleosides Nucleotides Nucleic Acids; 2018 Mar; 37(3):186-198. PubMed ID: 29608403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.